MiMedx Files S-4 for $350M Sanara Acquisition — $300M Debt Financing, Q4 Close Targeted
MDXG sits 43% above its 52-week low of $3.025.
Summary
MiMedx filed its S-4 for the $350M Sanara MedTech acquisition, detailing $33.00 cash plus 0.4735 shares per Sanara share, a $300M Hayfin term loan, and Q4 2026 closing. HSR review expires September 11.
Key Events · M&A and Partnerships · MDXG
-
S-4 Filed for $350M Sanara Acquisition
MiMedx registered up to 4.5M shares for the merger, with Sanara shareholders receiving $33.00 cash plus 0.4735 MiMedx shares per share — a 35% premium to Sanara's pre-announcement close.
-
$300M Hayfin Term Loan Secured
The cash portion is funded by a $300M first lien senior secured term loan from Hayfin Capital Management at SOFR + 6.25% initially. Pro forma long-term debt rises from $15.7M to $293M.
-
HSR Review Expires September 11
Parties filed HSR notifications August 12, 2026. The 30-day waiting period expires September 11, 2026, with closing expected in Q4 2026.
-
Termination Fees Set
Sanara pays $9.66M if it accepts a superior proposal; MiMedx pays $22.54M if it fails to close. The deal is not conditioned on financing.
Analysis · MDXG · Industrial Applications And Services
The formal S-4 registration statement for the $350 million acquisition of Sanara MedTech has been filed, moving the deal from announcement to execution. The filing locks in the merger consideration at $33.00 cash plus 0.4735 MiMedx shares per Sanara share, and reveals the financing structure: a $300 million first lien senior secured term loan from Hayfin Capital Management. The HSR waiting period expires September 11, 2026, with closing expected in Q4 2026. For MiMedx shareholders, this is a transformative acquisition that roughly doubles the company's revenue base but adds significant leverage — the pro forma balance sheet shows long-term debt jumping from $15.7 million to $293 million. The deal is not conditioned on financing, meaning MiMedx must close even if the debt markets tighten, though Hayfin's commitment is fully documented. Sanara shareholders get a 35% premium to the pre-announcement price, with 94% of consideration in cash providing certainty of value.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 37.4% of the 3413 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDXG was trading at $4.33 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $622.4M. The 52-week trading range was $3.03 to $7.97. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.